# Repibresib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/repibresib

> Repibresib, sponsored by Yarrow Bioscience, Inc. (YARW): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | repibresib |
| Codes | VYN201 |
| Sponsor | Yarrow Bioscience, Inc. (YARW) https://sec-api.dev/companies/yarw/catalysts |
| Indications | nsv in november 2022 |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2022: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: NSV in November 2022.
- First seen 2025-03-06, last confirmed 2025-05-08.
- SEC Form 10-Q (accession 0001628280-25-023740): "In November 2022, we initiated a Phase 1 clinical trial evaluating a topical formulation of repibresib first in healthy volunteers (Phase 1a) and then in subjects (Phase 1b) with nonsegmental vitiligo (NSV), an immune-mediated condition that has a high unmet need and only one approved therapy." https://www.sec.gov/Archives/edgar/data/1566044/000162828025023740/vyne-20250331.htm
- SEC Form 10-K (accession 0001628280-25-010908): "In November 2022, we initiated a Phase 1 clinical trial evaluating a topical formulation of repibresib first in healthy volunteers (Phase 1a) and then in subjects (Phase 1b) with nonsegmental vitiligo (NSV), an immune-mediated condition that has a high unmet need and only one approved therapy." https://www.sec.gov/Archives/edgar/data/1566044/000162828025010908/vyne-20241231.htm
- SEC Form 10-K (accession 0001628280-25-010908): "Based in part on the data we observed from the preclinical vitiligo model described below, we commenced a Phase 1 clinical trial evaluating repibresib topical ointment for the treatment of NSV in November 2022." https://www.sec.gov/Archives/edgar/data/1566044/000162828025010908/vyne-20241231.htm

### mid-2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-01-13, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-023478): "•Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025" https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/vyne-20250508q12025exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010777): "•Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025" https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/vyne-20250306q42024exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002862): "Repibresib (VYN201): Phase 2b trial initiated in Q2 2024, with top-line results anticipated in mid-2025" https://www.sec.gov/Archives/edgar/data/1566044/000110465925002862/tm252956d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-023478): "•Top-line results from the Phase 2b trial are expected in mid-2025." https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/vyne-20250508q12025exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010777): "In January, we announced the completion of enrollment in the Phase 2b trial of our locally administered pan-BD BET inhibitor, repibresib, in nonsegmental vitiligo, and we expect to report topline results in mid-2025." https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/vyne-20250306q42024exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-010777): "•Top-line results from the Phase 2b trial are expected in mid-2025." https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/vyne-20250306q42024exx991.htm
- SEC Form 10-Q (accession 0001628280-25-023740): "We enrolled approximately 45 patients in each arm and expect to report top-line results from the 24-week double-blind portion of the trial in mid-2025." https://www.sec.gov/Archives/edgar/data/1566044/000162828025023740/vyne-20250331.htm
- SEC Form 10-K (accession 0001628280-25-010908): "We enrolled approximately 45 patients in each arm and expect to report top-line results from the 24-week double-blind portion of the trial in mid-2025." https://www.sec.gov/Archives/edgar/data/1566044/000162828025010908/vyne-20241231.htm
- SEC Form 10-K (accession 0001628280-25-010908): "We anticipate top-line results from the 24-week double-blind portion of the trial to be available in mid-2025." https://www.sec.gov/Archives/edgar/data/1566044/000162828025010908/vyne-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/repibresib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Repibresib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/repibresib

```bibtex
@misc{secapidev_pdufa_repibresib_20261116,
  title        = {Repibresib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/repibresib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_repibresib_20261116","title":"Repibresib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/repibresib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
